🟠 Shares of #IntelliaTherapeutics (#NASDAQ:#NTLA) hit a 52-week low after announcing a 27% workforce reduction and halting its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease.
#CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA